title: [Psychopharmacotherapy of patients with arterial hypertension complicated with metabolic disturbances and depression].
abstract: Thirty-six patients with arterial hypertension complicated with disturbances of carbohydrate metabolism (from changes of tolerance to glucose to diabetes mellitus type II), lipid metabolism (obesity of different degree) and depression have been studied. In 23 cases (main group), a combined therapy with somatotropic and psychotropic drugs was used while 13 patients were (control group) treated only with somatotropic medications. Citalopram, a selective inhibitor of serotonin reuptake, was the main psychopharmacological drug used in the treatment of the main group. In some cases other medications (neuroleptics, benzodiazepines) were used. Patient's state was assessed by the results of the somatic and psychopathological examination using psychometric scales and by a number of indices obtained in the instrumental and laboratory (biochemical etc) study. The results suggest the higher efficacy of the combined therapy by all parameters--arterial pressure, indices of carbohydrate and lipid metabolism, severity of affective disorders.
authors: B D
authors: BD
authors: Tsygankov
authors: I E
authors: IE
authors: Chazova
authors: E O
authors: EO
authors: Poliakova
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D015283:Citalopram / Q000627:therapeutic use; D003863:Depression / Q000150:complications / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D015283:Citalopram; D000960:Hypolipidemic Agents; D017367:Selective Serotonin Reuptake Inhibitors